Examining biomarkers in children with asthma
The Role of Biomarkers in the Occurrence and Development of Asthma
This study is testing if certain markers in the blood can help us understand how severe asthma is in children compared to healthy kids.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2 (estimated) |
| Ages | 4 Years to 12 Years |
| Sex | All |
| Sponsor | Children's Hospital of Chongqing Medical University Academic / other |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Trial ID | NCT05768399 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the expression levels of biomarkers, specifically GITRL, in the peripheral blood of children diagnosed with asthma. It will compare these levels with those of healthy children to analyze their correlation with asthma severity. The study will recruit 30 children with asthma and 30 healthy controls, collecting blood samples and clinical data to assess the predictive value of biomarkers for asthma occurrence and development. The severity of asthma will be evaluated using spirometry and the C-CAT score.
Who should consider this trial
Good fit: Ideal candidates are children aged 4-12 years with a diagnosis of asthma or recurrent episodes.
Not a fit: Patients with other respiratory diseases or significant comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide new diagnostic and predictive tools for managing asthma in children.
How similar studies have performed: Other studies have shown promise in using biomarkers for asthma diagnosis and management, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * In line with the diagnostic criteria in the Guidelines for the Diagnosis and Prevention of Bronchial Asthma in Children (2016 Edition) * Age: 4-12 years old for new diagnosis or recurrent episodes * Typical clinical manifestations and complete clinical data * Family members or guardians of children with informed research and signed consent * All healthy control subjects had no history of lung disease, allergic rhinitis or any other atopic disease Exclusion Criteria: * Suffering from other respiratory diseases (such as bronchiectasis, allergic rhinitis, respiratory failure, tuberculosis, obstructive airway disease) or other inflammatory diseases. * Abnormal development of congenital airway and lung tissue * History of immunosuppressant or glucocorticoid use in the first 4 weeks * Suffering from other endocrine system and immune system diseases * Incomplete clinical data or examinations.
Where this trial is running
Chongqing, Chongqing Municipality
- Shaoqing Zhang — Chongqing, Chongqing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Ding Fengxia, PhD
- Email: dingfengxia305@163.com
- Phone: 86-15178712548
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.